NZ747693A - Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors - Google Patents

Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors

Info

Publication number
NZ747693A
NZ747693A NZ747693A NZ74769317A NZ747693A NZ 747693 A NZ747693 A NZ 747693A NZ 747693 A NZ747693 A NZ 747693A NZ 74769317 A NZ74769317 A NZ 74769317A NZ 747693 A NZ747693 A NZ 747693A
Authority
NZ
New Zealand
Prior art keywords
derivatives
riboside
nicotinic acid
nicotinamide
ribofuranosyl
Prior art date
Application number
NZ747693A
Other languages
English (en)
Inventor
Troy Rhonemus
Ryan Dellinger
Mark Morris
Aron Erickson
Hadi Cassier
Marie Migaud
Original Assignee
Chromadex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc filed Critical Chromadex Inc
Publication of NZ747693A publication Critical patent/NZ747693A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
NZ747693A 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors NZ747693A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662325264P 2016-04-20 2016-04-20
PCT/US2017/028673 WO2017184885A1 (en) 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors

Publications (1)

Publication Number Publication Date
NZ747693A true NZ747693A (en) 2023-07-28

Family

ID=60088650

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ747693A NZ747693A (en) 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors

Country Status (13)

Country Link
US (1) US10183036B2 (enExample)
EP (1) EP3445359B8 (enExample)
JP (3) JP7089480B2 (enExample)
KR (1) KR20190008246A (enExample)
CN (1) CN109640984A (enExample)
AU (2) AU2017254657A1 (enExample)
BR (1) BR112018071573A2 (enExample)
CA (1) CA3021571C (enExample)
ES (1) ES2948968T3 (enExample)
MX (1) MX393076B (enExample)
NZ (1) NZ747693A (enExample)
WO (1) WO2017184885A1 (enExample)
ZA (1) ZA201807736B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011788A1 (en) * 2015-07-15 2017-01-19 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
BR112018002168B1 (pt) 2015-08-05 2023-10-10 Metro International Biotech, Llc Composto, ou um estereoisômero ou sal do mesmo, uso do composto e composição que compreende um composto ou um sal farmaceuticamente aceitável do mesmo
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
EP3538099A4 (en) 2016-11-11 2020-06-17 The Queen's University of Belfast EFFICIENT AND SCALABLE SYNTHESIS OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS OF THEM, ADENYLYDINUCLEOTIDE CONJUGATES THEREOF AND NEW-WAY CRYSTALS
CN110234238B (zh) 2016-11-29 2023-03-28 爱荷华大学研究基金会 Nad前体用于改善母体健康和/或后代健康的用途
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
WO2018191771A1 (en) * 2017-04-18 2018-10-25 Victor Chang Cardiac Research Institute Detection and treatment of congenital malformations
SG11201912267SA (en) 2017-06-19 2020-01-30 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
AU2019214858B2 (en) * 2018-01-30 2023-02-02 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
EP3797110A1 (en) * 2018-05-22 2021-03-31 Jumpstart Fertility Pty Ltd Amino acid salts of nicotinic acid ribosides as anti-aging agents
US11833167B2 (en) 2018-12-17 2023-12-05 Mitopower Llc Nicotinyl riboside compounds and their uses
CN113727987A (zh) * 2019-02-21 2021-11-30 可劳迈戴斯有限公司 烟酰胺核苷、烟酸核苷、还原型烟酰基核苷化合物和烟酰基核苷化合物衍生物在制品的用途
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
JP2022534863A (ja) * 2019-06-05 2022-08-04 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 骨格筋の疾患を治療／予防するための還元型ニコチンアミドリボシド
US20220323468A1 (en) * 2019-06-05 2022-10-13 Societe Des Produits Nestle S.A. Reduced nicotinamideribosides for the treatment/prevention of liver disease
WO2020245187A1 (en) * 2019-06-05 2020-12-10 Société des Produits Nestlé S.A. Reduced nicotinamideribosides for treating or preventing kidney disease
CN110973260A (zh) * 2019-12-11 2020-04-10 杨力 一种含有烟酰胺核糖苷的牛奶及其制备方法与应用
WO2021123245A1 (en) 2019-12-19 2021-06-24 Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) Nad-precursors and dietary restriction for treating age-related medical conditions
CN115066246B (zh) * 2020-03-09 2025-11-28 雀巢产品有限公司 包含用于预防和治疗病毒和细菌感染的还原型烟酰胺核糖核苷的组合物和方法
EP4117677A1 (en) * 2020-03-09 2023-01-18 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions
WO2021180741A1 (en) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of pancreatic diseases and conditions
WO2021180732A1 (en) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of neurological diseases and conditions
CN114561342B (zh) * 2020-11-27 2024-12-20 西安交通大学医学院第一附属医院 Nad信号通路激动剂在体外胚胎培养中的应用
CN112716969B (zh) * 2021-01-15 2022-11-29 江苏恒正合生命科学有限公司 治疗阿尔茨海默症的组合物及其制备方法、应用
CA3213831A1 (en) * 2021-05-05 2022-11-10 Carles Canto Alvarez Composition and methods using combination of narh and nr to produce intracellular nicotinamide adenine dinucleotide (nad+)
CN117545488A (zh) 2021-05-27 2024-02-09 麦德龙国际生物科技有限责任公司 烟酸单核苷酸及其酯的结晶固体以及其制作和使用方法
JP2024523126A (ja) * 2021-06-18 2024-06-28 ミトパワー エルエルシー Ｎｒｈ、ｎａｒｈ、及びそれらの還元誘導体を用いた免疫関連障害、腎障害、肝障害、溶血性障害、及び酸化的ストレス関連障害の処置
EP4422644A4 (en) * 2021-10-27 2025-08-27 Elysium Health Inc METHODS OF TREATING MENOPAUSAL SYNDROMES
JP7111878B1 (ja) 2021-10-27 2022-08-02 旭化成ファーマ株式会社 ニコチンアミドモノヌクレオチドの製造方法
WO2023150072A1 (en) 2022-02-01 2023-08-10 Sinclair David A Compositions and methods for the preservation of plant matter
EP4472993A2 (en) * 2022-02-04 2024-12-11 Elysium Health, Inc. Ribose linkers and conjugates thereof
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022680B2 (en) * 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7927859B2 (en) 2003-08-22 2011-04-19 Rice University High molar succinate yield bacteria by increasing the intracellular NADH availability
JP2007521835A (ja) 2004-02-10 2007-08-09 トラスティーズ・オブ・ダートマウス・カレッジ ニコチンアミドリボシドキナーゼ組成物およびそれらの使用方法
ES2557810T3 (es) 2004-06-04 2016-01-28 Washington University Métodos y composiciones para tratar neuropatías
ES2670927T3 (es) * 2005-11-18 2018-06-04 Cornell Research Foundation, Inc. Composiciones de nicotinoil ribósido y métodos de uso
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
CN105873937A (zh) 2013-10-30 2016-08-17 可劳迈戴斯有限公司 用于在治疗皮肤病中局部使用的烟酰胺核苷组合物
RU2016149767A (ru) 2014-06-06 2018-07-16 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед Аналоги никотинамидрибозида и фармацевтические композиции и их применение
US10280190B2 (en) * 2015-03-16 2019-05-07 Chromadex, Inc. Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions
WO2017011788A1 (en) 2015-07-15 2017-01-19 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
BR112018002168B1 (pt) 2015-08-05 2023-10-10 Metro International Biotech, Llc Composto, ou um estereoisômero ou sal do mesmo, uso do composto e composição que compreende um composto ou um sal farmaceuticamente aceitável do mesmo
CN115176998A (zh) * 2016-04-14 2022-10-14 可劳迈戴斯有限公司 烟酰胺核苷、烟酸核苷、烟酰胺单核苷酸和烟碱基化合物衍生物在婴儿配方中的用途

Also Published As

Publication number Publication date
EP3445359B8 (en) 2023-09-06
ES2948968T3 (es) 2023-09-22
JP2019514874A (ja) 2019-06-06
AU2022221384C1 (en) 2023-08-03
WO2017184885A1 (en) 2017-10-26
EP3445359C0 (en) 2023-06-07
KR20190008246A (ko) 2019-01-23
JP7493007B2 (ja) 2024-05-30
CA3021571C (en) 2023-01-03
MX2018012849A (es) 2019-08-29
CA3021571A1 (en) 2017-10-26
JP2021176871A (ja) 2021-11-11
ZA201807736B (en) 2020-05-27
AU2017254657A1 (en) 2018-11-15
MX393076B (es) 2025-03-24
AU2022221384A1 (en) 2022-09-22
WO2017184885A8 (en) 2023-08-24
BR112018071573A2 (pt) 2019-02-12
AU2022221384B2 (en) 2023-03-23
JP7089480B2 (ja) 2022-06-22
US10183036B2 (en) 2019-01-22
US20170304338A1 (en) 2017-10-26
JP2023002685A (ja) 2023-01-10
EP3445359B1 (en) 2023-06-07
EP3445359A4 (en) 2019-12-25
CN109640984A (zh) 2019-04-16
EP3445359A1 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
NZ747693A (en) Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors
BR112017019696A2 (pt) composto e usos de um composto
EA201890435A1 (ru) Производные никотинамидмононуклеотида и их применение
WO2020131578A3 (en) Nicotinyl riboside compounds and their uses
BR112012020742A2 (pt) derivados de pirazolo piperidina como inibidores de nadph oxidase.
MX2015005949A (es) Nucleosidos que contienen aza-azucar antiviral.
ZA202106912B (en) Use of nicotinamide riboside, nicotinic acid riboside, reduced nicotinyl riboside compounds, and nicotinyl riboside compound derivatives in formulations
PL2007429T3 (pl) Doustna kompozycja o korzystnym działaniu sercowo-naczyniowym, zawierająca berberynę
NZ739339A (en) Apoptosis signal-regulating kinase inhibitor
WO2010123591A3 (en) Small molecule inhibitors of nads, namnat, and nmnat
TW200607804A (en) Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
WO2010035219A3 (en) Pyrazolo pyridine derivatives as nadph oxidase inhibitors
PH12014501134A1 (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
MX2010009922A (es) Activadores de piridazinona glucocinasa.
MY170437A (en) Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
MX2015008837A (es) Composiciones parenterales estables de dnj.
Endo et al. Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3
MX2010005198A (es) Composiciones liquidas que comprenden valsartan.
DOP2010000342A (es) Compuestos conteniendo nitrogeno triciclico y sus usos como antibacteriales
AU2017241626A1 (en) Viable cell compositions, and methods related to same
WO2006072809A3 (en) Formulations that optimize intracellular concentration of nicotinamide adenine (nad+) and methods of use to protect cells and treat diseases and conditions
WO2024259359A3 (en) Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof
BR112021024663A2 (pt) Composições e métodos que usam trigonelina para produzir nad+ intracelular
DE602005007380D1 (de) Formulierung für die orale verabreichung mit gesundheitsfördernder wirkung auf das herz-kreislauf-system
WO2011103586A3 (en) Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with 7-hydroxystaurosporine

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 APR 2025 BY COMPUTER PACKAGES INC

Effective date: 20240417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 APR 2026 BY COMPUTER PACKAGES INC

Effective date: 20250417